The 2012 American College of Rheumatology gout treatment guidelines recommend titration of urate-lowering medication doses to achieve target serum uric acid (sUA) levels of less than 6 mg/dL. Analysis ...

In patients with gout, a novel prediction tool that relies on weight and creatinine clearance successfully identified the dose of allopurinol required to achieve a serum urate (SU) level < 6 mg/dL in ...

Trial subgroup analyses support the use of either allopurinol or febuxostat in patients with stage 3 CKD and gout. A prespecified analysis of the STOP-GOUT trial revealed that allopurinol has similar ...

A study of over 100,000 gout patients has found that urate-lowering drugs, particularly allopurinol, are linked to a significant reduction in the risk of heart attack and stroke when taken at the ...

Credit: Getty Images. The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are ...

Benzbromarone, a urate-lowering drug, appeared effective among patients with high serum uric acid levels who had no evidence of gout flares. Benzbromarone may reduce the risk of developing chronic ...